Adeel discusses the revolutionary gene therapy that targets sarcopenia, the loss of muscle with age. By increasing follistatin levels, the therapy inhibits myostatin, promoting muscle growth and reducing systemic inflammation. The phase one trial showed a remarkable reduction in biological age, hinting at potential longevity benefits.
